Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
NORCROSS, Ga., March 09, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:30 a.m. Pacific Time. The conference is being held at the Ritz-Carlton in Dana Point, CA on March 12-15, 2017.
A live webcast of the presentation may be accessed on the conference’s website at http://wsw.com/webcast/roth31/galt. The webcast will be archived for 365 days following the live presentation on the Company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
